Thermo Fisher sells lab division to PE firm for $480M; Dental laser company Biolase raises $12M;

@FierceMedDev: Profit stumble pushes Philips to focus on healthcare. Article | Follow @FierceMedDev

@StacyALawrence: Miss Idaho wears insulin pump in swimsuit competition. Item | Follow @StacyALawrence

@VarunSaxena2: ICYMI yesterday: FDA approves expandable implant for spinal fusion surgery. News | Follow @VarunSaxena2

@MichaelGFierce: RT @EmilyMFierce: Which 15 disease areas get the most funding from NIH? Report | Follow @MichaelGFierce

@EmilyWFierce: Auditory brainstem implant provides alternative to cochlear device, offers profoundly deaf children a chance to hear. More from the Los Angeles Times | Follow @EmilyWFierce

> Thermo Fisher Scientific ($TMO) sold its Cole-Parmer laboratory division to private equity firm GTCR for $480 million. Story

> Dental laser company Biolase to raise $12 million in a private placement with investors including Oracle Partners and Birchview Capital. Release

> USGI Medical garnered a $9 million line of credit from GE Capital to help support its pivotal trial for its endospopic obesity device. Release

Biotech News

@FierceBiotech: $ZIOP, $XON tackle CAR-T in expanded partnership. More | Follow @FierceBiotech

@JohnCFierce: Biosimilars set to boom as new patent cliff on biologic superstars looms. Article | Follow @JohnCFierce

@DamianFierce: "It's like surfing. If you aren't in the water you'll never catch that monster wave." -- CEO on going public. More | Follow @DamianFierce

@EmilyMFierce: Which 15 disease areas get the most funding from NIH? List | Follow @EmilyMFierce

> AstraZeneca adds Advaxis to a growing roster of immuno-oncology partners. Story

> With a $650M gift and a trove of genomic data, Broad sets out to innovate in schizophrenia. Article

> Sage takes to the FDA fast track with its lead rare disease drug. News

> Atlas, NEA bankroll a $30M round for synthetic biology upstart Synlogic. Report

Pharma News

@FiercePharma: Top-read on FP Monday: Gilead litigation says claims by Merck, AbbVie on Sovaldi are patently wrong. Article | Follow @FiercePharma

@TracyStaton: ICYMI: CVS Caremark lays out case for new specialty-drug pricing approach in JAMA editorial. Story | Follow @TracyStaton

@EricPFierce: French animal health drugmaker Virbac sees US sales hurt by last year's recall of Iverhart Plus. More from FierceAnimalHealth | Follow @EricPFierce

@CarlyHFierce: Defensive Allergan plots 1,500 job cuts, hikes forecast to fight off Valeant. Report | Follow @CarlyHFierce

> News flash for biopharma bosses: More than half your employees want to leave. Story

> Cost-conscious payers are eyeing higher prices on diabetes drugs. Report

> Do testosterone meds boost heart attack risks? FDA asks advisory panels to weigh the data. Article

> Touting a Q2 beat and strong Opsumit launch, Actelion CEO dismisses takeover chatter. More

Biotech Research News

> Top 15 NIH-funded disease areas. Report

> Simulated human heart aims to screen drugs for adverse effects. More

> First U.S.-acquired chikungunya case detected. Item

> Simulated human heart aims to screen drugs for adverse effects. Article

> Enzyme may provide new target for Alzheimer's disease. Story

Pharma Manufacturing News

> FedEx to fight charges it was key link in supply chain for illegal drugs. News

> FDA again warns that Texas compounder's products may not be sterile. Item

> GSK, J&J push for genetic engineering of opium. More

> American Health recalls epilepsy drug and ibuprofen over possible tablet switch. Story

> Lilly to cut 100 production jobs in Indianapolis, but workers get shot at others. Article

Suggested Articles

Flatiron has hired a new chief medical officer as it looks to push on under its new parent in the world of electronic health records and real-world data.

Saga Diagnostics has raised 40 million Swedish kronor, or about $4.1 million, to help develop its ultrasensitive cancer liquid biopsy tests.

Terumo will help Orchestra BioMed develop its sirolimus-eluting balloon in both coronary and peripheral cardiovascular interventions.